{"id":4983,"date":"2015-11-16T13:49:24","date_gmt":"2015-11-16T13:49:24","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=4983"},"modified":"2015-11-16T13:49:24","modified_gmt":"2015-11-16T13:49:24","slug":"amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/","title":{"rendered":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC)"},"content":{"rendered":"<p><strong><a href=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4849\" src=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg\" alt=\"amgen\" width=\"300\" height=\"83\" srcset=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg 300w, https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg 338w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/strong><\/p>\n<p><strong>I<\/strong><strong>M<\/strong><strong>L<\/strong><strong>Y<\/strong><strong>GIC este prima imunoterapie oncolitic\u0103 care demonstreaz\u0103 beneficii terapeutice pentru pacien\u0163ii cu melanom avansat<\/strong><\/p>\n<p><strong>THOUSAND OAKS, Calif. (16 noiembrie 2015)<\/strong> \u2013 Amgen a anun\u0163at c\u0103 CHMP (Comitetul pentru Medicamente de Uz Uman) din cadrul Agen\u021biei Europene pentru Medicamente (EMA), a adoptat o opinie favorabil\u0103, recomand\u00e2nd ca IMLYGIC\u2122 (talimogene laherparepvec) s\u0103 fie aprobat pentru tratamentul adul\u0163ilor cu melanom nerezecabil, cu metastaze regionale sau la distan\u0163\u0103 (stadiul IIIB, IIIC \u015fi IVM1a) f\u0103r\u0103 alte afec\u0163iuni osoase, cerebrale, pulmonare sau viscerale. Dac\u0103 prime\u015fte aprobarea Comisiei Europene, IMLYGIC ar fi primul dintr-o clas\u0103 de agen\u0163i noi cunoscu\u0163i sub numele de imunoterapii oncolitice.<\/p>\n<p>IMLYGIC, administrat prin injec\u0163ie intralezional\u0103, este conceput s\u0103 omoare celulele tumorale \u015fi s\u0103 declan\u015feze un r\u0103spuns imun antitumoral.<\/p>\n<p>\u201eSuntem mul\u0163umi\u0163i c\u0103 IMLYGIC a primit un aviz favorabil din partea CHMP \u015fi, dac\u0103 prime\u015fte aprobarea Comisiei Europene, a\u015ftept\u0103m cu ner\u0103bdare s\u0103 continu\u0103m colaborarea cu autorit\u0103\u0163ile de reglementare europene pentru a aduce aceast\u0103 terapie inovatoare pe pia\u021b\u0103, \u00een beneficiul pacien\u0163ilor,\u201d a declarat Dr. Sean E. Harper, vice pre\u015fedinte executiv pe probleme de cercetare \u015fi dezvoltare \u00een cadrul Amgen. \u201eMelanomul metastatic continu\u0103 s\u0103 fie unul dintre tipurile de cancer cel mai dificil de tratat, necesit\u00e2nd adesea utilizarea mai multor metode de tratament. \u00cen pofida progreselor recente, rata de supravie\u0163uire de cinci ani pentru pacien\u0163ii care nu pot beneficia de tratament chirurgical r\u0103m\u00e2ne inacceptabil de sc\u0103zut\u0103, demonstr\u00e2nd necesitatea imperativ\u0103 de identificare a abord\u0103rilor suplimentare pentru a \u0163ine aceast\u0103 boal\u0103 sub control.\u201d<\/p>\n<p>La baza avizului favorabil din partea CHMP a stat un studiu clinic deschis, randomizat, global, de faz\u0103 III, de evaluare a siguran\u0163ei \u015fi eficacit\u0103\u0163ii IMLYGIC la pacien\u0163ii cu melanom \u00een stadiul IIIB, IIIC sau IV, atunci c\u00e2nd nu s-a recomandat rezec\u0163ia, comparativ cu factorul de stimulare a cre\u0219terii coloniilor de granulocite macrofage (GM-CSF). \u00cen studiul derulat pe 436 de pacien\u0163i, IMLYGIC a \u00eembun\u0103t\u0103\u0163it semnificativ rata de r\u0103spuns durabil (<em>durable response rate<\/em> &#8211; DRR), obiectivul clinic primar al studiului, la popula\u0163ia \u00een inten\u0163ie de tratament. DRR este definit ca procentul de pacien\u0163i cu r\u0103spuns complet (<em>complete response<\/em> &#8211; CR) sau r\u0103spuns par\u0163ial (<em>partial response<\/em> &#8211; PR) men\u0163inut continuu cel pu\u0163in \u015fase luni. Un obiectiv clinic secundar cheie a fost supravie\u0163uirea global\u0103 (<em>o<\/em><em>verall survival<\/em> &#8211; OS). Avizul favorabil al CHMP reflect\u0103 analizele de subgrup \u00een care OS a fost cea mai \u00eenalt\u0103 la pacien\u0163ii cu melanom nerezecabil a c\u0103rui r\u0103sp\u00e2ndire nu a dep\u0103\u015fit pielea sau ganglionii limfatici.<\/p>\n<p>Reac\u0163iile adverse asociate cu tratamentul raportate cel mai frecvent au fost: oboseala, frisoanele, pirexia, grea\u0163a, simptomele gripale \u015fi durere la locul inject\u0103rii. Per total, 98% dintre aceste reac\u0163ii adverse raportate au fost u\u015foare sau moderate. Cea mai frecvent\u0103 reac\u0163ie advers\u0103 de grad 3 sau superior a fost celulita.<\/p>\n<p>Melanomul este un tip de cancer de piele caracterizat de dezvoltarea necontrolat\u0103 a melanocitelor, acestea fiind celulele responsabile pentru pigmentarea pielii.1 Melanomul este cea mai grav\u0103 \u015fi mai agresiv\u0103 form\u0103 de cancer de piele \u015fi r\u0103m\u00e2ne o problem\u0103 de s\u0103n\u0103tate public\u0103 \u00een Uniunea European\u0103 (UE).2,3 S-a estimat c\u0103, \u00een 2012, s-au \u00eenregistrat 56.000 cazuri noi de melanom \u00een Fran\u0163a, Italia, Spania, Germania \u015fi Marea Britanie, conduc\u00e2nd la aproximativ 9.500 de decese.4,5<\/p>\n<p>\u00cen urma acestui aviz din partea CHMP, Amgen a\u015fteapt\u0103 \u00een lunile urm\u0103toare o decizie privind Autoriza\u0163ia de punere pe pia\u0163\u0103 din partea Comisiei Europene. IMLYGIC se afl\u0103 de asemenea \u00een curs de evaluare la Administra\u0163ia pentru Alimente \u015fi Medicamente din SUA.<\/p>\n<p><strong>Despre<\/strong> <strong>IM<\/strong><strong>LYGIC (talimogene laherparepvec) \u00een UE<\/strong><\/p>\n<p>IMLYGIC este o imunoterapie oncolitic\u0103 derivat\u0103 din HSV-1, cunoscut uzual ca virus herpetic. IMLYGIC a fost modificat pentru a se replica \u00een tumori \u015fi pentru a produce proteina de stimulare a sistemului imunitar uman, GM-CSF. IMLYGIC omoar\u0103 celulele tumorale \u015fi determin\u0103 eliberarea antigenilor deriva\u0163i din tumori. Exist\u0103 ipoteze conform c\u0103rora, \u00eempreun\u0103 cu GM-CSF, va promova un r\u0103spuns imun antitumoral sistemic \u015fi un r\u0103spuns al celulelor T efectoare.<\/p>\n<p><strong>Despre<\/strong> <strong>IM<\/strong><strong>LYGIC (talimogene laherparepvec) \u00een SUA<\/strong><\/p>\n<p>IMLYGIC este un virus herpes simplex de tip 1 modificat genetic, injectat direct \u00een tumori. IMLYGIC se replic\u0103 \u00een interiorul celulelor tumorale \u015fi produce GM-CSF, o protein\u0103 imunostimulatoare. IMLYGIC determin\u0103 apoi dezagregarea \u015fi moartea celulei printr-un proces cunoscut sub numele de liz\u0103. Dezagregarea celulelor canceroase conduce la eliberarea antigenilor deriva\u0163i din tumoare care, \u00eempreun\u0103 cu GM-CSF derivat\u0103 viral, pot contribui la \u00eencurajarea unui r\u0103spuns imun antitumoral. Nu se cunoa\u015fte \u00eens\u0103 mecanismul de ac\u0163iune exact.<\/p>\n<p><strong>Despre parteneriatele derulate de<\/strong> <strong>A<\/strong><strong>mgen av\u00e2nd \u00een prim plan imuno-oncologia<\/strong><\/p>\n<p>Amgen a implementat un program complex de dezvoltare clinic\u0103 care investigheaz\u0103 poten\u0163ialul imunoterapiilor oncolitice \u00een melanom \u015fi \u00eentr-o varietate de alte tipuri de cancer.<\/p>\n<p>Parteneriatele derulate recent de Amgen av\u00e2nd \u00een prim plan imuno-oncologia includ:<\/p>\n<ul>\n<li>O <a href=\"http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?releaseID=2054439\">colaborare cu Merck <\/a>pentru dezvoltarea IMLYGIC \u015fi KEYTRUDA\u00ae (pembrolizumab), terapia anti-PD-1 oferit\u0103 de Merck, \u00een melanom \u015fi cancer de cap \u015fi g\u00e2t cu celule scuamoase.<\/li>\n<li>O <a href=\"http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?releaseID=2055362\">colaborare cu Roche <\/a>privind un studiu de faz\u0103 1b de evaluare a siguran\u0163ei \u015fi eficacit\u0103\u0163ii IMLYGIC \u00een combina\u0163ie cu terapia investiga\u0163ional\u0103 anti-PDL1 de la Roche, atezolizumab (cunoscut \u015fi ca MPDL3280A), la pacien\u0163ii cu diagnostic de cancer mamar triplu negativ \u015fi cancer colorectal cu metastaze hepatice.<\/li>\n<li>Un <a href=\"http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2015&amp;amp;releaseID=2002967\">acord strategic de licen\u0163\u0103 \u015fi colaborare <\/a>\u00een cercetare \u00eencheiat cu Kite Pharma pentru dezvoltarea \u015fi comercializarea urm\u0103toarei genera\u0163ii de imunoterapii noi cu limfocite T &#8211; receptori de antigen chimeric (CAR).<\/li>\n<li>Un <a href=\"http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2015&amp;amp;releaseID=2002967\">acord de colaborare <\/a>\u00een cercetare \u00eencheiat cu <u>M<\/u><u>D Anderson\u2019s Moon Shots Program, <\/u>av\u00e2nd \u00een centru constructele de anticorpibi-specifici Amgen de mobilizare a limfocitelor T (BiTE\u00ae).<\/li>\n<li><a href=\"http:\/\/wwwext.amgen.com\/media\/media_pr_detail.jsp?year=2015&amp;amp;releaseID=2088189\">Un acord de cercetare \u015fi licen\u0163\u0103 \u00eencheiat cu Xencor <\/a>pentru dezvoltarea \u015fi comercializarea agen\u0163ilor terapeutici noi \u00een domeniul imunoterapiei \u00een cancer \u015fi al inflama\u0163iei. Colaborarea pentru cercetare reune\u015fte capacit\u0103\u0163ile Amgen \u00een descoperirea \u0163intit\u0103 \u015fi agen\u0163ii terapeutici pe baz\u0103 de proteine cu platforma de tehnologie bi-specific\u0103 XmAb\u00ae de la Xencor.<\/li>\n<\/ul>\n<p><strong>Despre<\/strong> <strong>A<\/strong><strong>mgen<\/strong><\/p>\n<p>Amgen se angajeaz\u0103 s\u0103 elibereze poten\u0163ialul biologiei pentru pacien\u0163ii care sufer\u0103 de boli grave prin descoperirea, dezvoltarea, fabricarea \u015fi furnizarea agen\u0163ilor terapeutici umani inovatori. \u00a0Aceast\u0103 abordare \u00eencepe cu utilizarea instrumentelor precum genetica uman\u0103 avansat\u0103 pentru a deslu\u015fi complexitatea bolii \u015fi pentru a \u00een\u0163elege fundamentele biologiei umane.<\/p>\n<p>Amgen pune accentul pe domenii \u00een care cerin\u0163ele medicale sunt foarte slab satisf\u0103cute \u015fi se folose\u015fte de expertiza sa \u00een produc\u0163ia de agen\u0163i biologici pentru a g\u0103si solu\u0163ii care \u00eembun\u0103t\u0103\u0163esc nivelul st\u0103rii de s\u0103n\u0103tate \u015fi \u00eembun\u0103t\u0103\u0163esc dramatic vie\u0163ile oamenilor. Pionier\u0103 \u00een biotehnologie din 1980, compania Amgen s-a dezvoltat, devenind una dintre principalele companii independente din domeniul biotehnologiei la nivel mondial, \u015fi a ajuns la milioane de pacien\u0163i din toat\u0103 lumea iar \u00een prezent dezvolt\u0103 un \u201epipeline\u201d de medicamente cu poten\u0163ial inovator.<\/p>\n<p>Pentru mai multe informa\u0163ii, vizita\u0163i \u00a0<a href=\"http:\/\/www.amgen.com\/\">www.amgen.com <\/a>\u015fi urm\u0103ri\u0163i-ne pe pagina \u00a0<a href=\"http:\/\/www.twitter.com\/amgen\">www.twitter.com\/amgen<\/a>.<\/p>\n<p><strong>Despre angajamentul<\/strong> <strong>A<\/strong><strong>mgen fa\u0163\u0103 de oncologie<\/strong><\/p>\n<p>Amgen Oncologie se angajeaz\u0103 s\u0103 ajute pacien\u0163ii s\u0103 lupte cu unele dintre cele mai dure tipuri de cancer, precum cele rezistente la medicamente, cele care evolueaz\u0103 rapid \u00een organism \u015fi cele pentru care exist\u0103 op\u0163iuni de tratament limitate. Tratamentele paliative oferite de Amgen \u00eei ajut\u0103 pe pacien\u0163i s\u0103 combat\u0103 anumite reac\u0163ii adverse ale chimioterapiei puternice, iar medicamentele \u015fi imunoterapiile\u00a0 noastre vizeaz\u0103 mai mult de o duzin\u0103 de afec\u0163iuni maligne diferite, de la cancer de s\u00e2nge la tumori solide. Av\u00e2nd decenii de experien\u0163\u0103 \u00een tratamentul pacien\u0163ilor cu diagnostic de cancer, Amgen continu\u0103 s\u0103 \u00ee\u015fi l\u0103rgeasc\u0103 portofoliul de medicamente oncologice biosimilare \u015fi inovatoare.<\/p>\n<p><strong>Declara\u0163ii anticipative<\/strong><\/p>\n<p>Acest comunicat de pres\u0103 con\u0163ine declara\u0163ii anticipative la baza c\u0103rora se afl\u0103 a\u015ftept\u0103rile \u015fi convingerile actuale ale Amgen Inc. \u015fi ale subsidiarelor sale (Amgen sau noi) \u015fi se afl\u0103 sub rezerva unui num\u0103r de riscuri, incertitudini \u015fi presupuneri care ar putea conduce la diferen\u0163e semnificative \u00eentre rezultatele efective \u015fi cele descrise. Toate declara\u0163iile, mai pu\u0163in cele ale faptelor istorice, sunt declara\u0163ii care pot fi considerate declara\u0163ii anticipative, inclusiv estim\u0103ri de venituri, marje de operare, cheltuieli de capital, numerar, alte unit\u0103\u0163i metrice financiare, rezultate sau practici preconizate, legale, de arbitraj, politice, de reglementare sau clinice, tipare sau practici ale clientului sau prescriptorului, activit\u0103\u0163i de compensare \u015fi rezultate \u015fi alte astfel de estim\u0103ri \u015fi rezultate. Declara\u0163iile anticipative implic\u0103 riscuri \u015fi incertitudini semnificative, inclusiv cele discutate \u00een continuare \u015fi descrise mai detaliat \u00een rapoartele Comisiei pentru Valori Mobiliare \u015fi Schimb (Securities and Exchange Commission &#8211; SEC) depuse de Amgen Inc., inclusiv cel mai recent raport anual al companiei Amgen Inc. pe Formularul 10-K \u015fi orice raport periodic ulterior pe Formularul 10-Q \u015fi Formularul 8-K. Pentru informa\u0163ii suplimentare privind incertitudinile \u015fi factorii de risc asocia\u0163i cu activitatea noastr\u0103, consulta\u0163i cele mai recente Formulare 10-K, 10-Q \u015fi 8-K depuse de Amgen. Dac\u0103 nu se specific\u0103 altfel, Amgen furnizeaz\u0103 aceste informa\u0163ii \u00eencep\u00e2nd cu 22 oct. 2015 \u015fi denun\u0163\u0103 \u00een mod expres orice obliga\u0163ie de a actualiza informa\u0163iile cuprinse \u00een acest comunicat de pres\u0103.<\/p>\n<p>Nicio declara\u0163ie anticipativ\u0103 nu poate fi garantat\u0103 iar rezultatele efective pot diferi semnificativ de cele pe care le preconiz\u0103m. Nu se poate garanta descoperirea sau identificarea unor candida\u0163i pentru produse noi sau dezvoltarea unor indica\u0163ii noi pentru produsele existente iar trecerea de la concept la produs este incert\u0103; \u00een consecin\u0163\u0103, nu pot exista garan\u0163ii c\u0103 un produs candidat sau dezvoltarea unei indica\u0163ii noi pentru un produs existent va avea succes \u015fi va deveni un produs comercial. Mai mult, rezultatele preclinice nu garanteaz\u0103 ac\u0163iunea sigur\u0103 \u015fi eficient\u0103 la oameni, a candidatelor la statutul de produs.<\/p>\n<p>Complexitatea corpului uman nu poate fi modelat\u0103 perfect \u015fi uneori adecvat de computer sau de sistemele de culturi celulare sau modelele pe animale. Timpul de care avem nevoie noi \u015fi partenerii no\u015ftri pentru a \u00eencheia studii clinice \u015fi pentru a ob\u0163ine aprobarea autorit\u0103\u0163ii de reglementare pentru comercializarea produselor a variat \u00een trecut \u015fi preconiz\u0103m o variabilitate similar\u0103 pe viitor. Dezvolt\u0103m intern produse candidate \u015fi prin colabor\u0103ri, parteneriate \u015fi asocieri de licen\u0163iere. Produsele candidate derivate din rela\u0163ii pot face obiectul litigiilor \u00eentre p\u0103r\u0163i sau se pot demonstra mai pu\u0163in eficiente \u015fi sigure dec\u00e2t am crezut la momentul angaj\u0103rii \u00eentr-o astfel de rela\u0163ie. De asemenea, noi sau al\u0163ii putem identifica siguran\u0163a, reac\u0163iile adverse sau probleme de fabrica\u0163ie la produsele noastre dup\u0103 punerea pe pia\u0163\u0103. Activitatea noastr\u0103 ar putea fi afectat\u0103 de investiga\u0163ii guvernamentale, litigii \u015fi preten\u0163ii de r\u0103spundere privind produsul. Dac\u0103 nu \u00eendeplinim obliga\u0163iile de conformitate din acordul de integritate corporativ\u0103 pe care l-am \u00eencheiat cu guvernul SUA, exist\u0103 riscul de fi sanc\u0163iona\u0163i sever. Depindem de ter\u0163e p\u0103r\u0163i pentru un procent semnificativ din capacitatea noastr\u0103 de produc\u0163ie pentru furnizarea unei p\u0103r\u0163i din produsele noastre actuale \u015fi viitoare, iar limitele noastre de furnizare ar putea constr\u00e2nge v\u00e2nzarea unora dintre produsele noastre actuale \u015fi dezvoltarea produselor candidate.<\/p>\n<p>\u00cen plus, v\u00e2nzarea produselor noastre (inclusiv produsele subsidiarelor noastre de\u0163inute integral) este afectat\u0103 de politicile de compensare impuse de pl\u0103titori ter\u0163\u0103 parte inclusiv guverne, planuri de asigur\u0103ri private \u015fi furnizori de \u00eengrijire gestionate \u015fi poate fi afectat\u0103 de dezvolt\u0103ri ale reglement\u0103rilor, clinice \u015fi ale ghidurilor \u015fi de tendin\u0163e na\u0163ionale \u015fi interna\u0163ionale spre \u00eengrijirea gestionat\u0103 \u015fi limitarea costurilor de asisten\u0163\u0103 medical\u0103, c\u00e2t \u015fi legisla\u0163ia SUA care afecteaz\u0103 pre\u0163urile \u015fi compensarea produselor farmaceutice. Reglement\u0103rile \u015fi politicile de guvernare ale guvernului \u015fi ale altor entit\u0103\u0163i pot afecta dezvoltarea, utilizarea \u015fi pre\u0163urile produselor noastre. \u00cen plus, concur\u0103m cu alte companii \u00een ceea ce prive\u015fte o parte din produsele noastre comercializate c\u00e2t \u015fi pentru descoperirea \u015fi dezvoltarea unor produse noi. Suntem de p\u0103rere c\u0103 unele dintre produsele noastre mai noi, candidatele la statutul de produse sau indica\u0163iile noi pentru produse existente pot face fa\u0163\u0103 concuren\u0163ei din momentul aprob\u0103rii \u015fi comercializ\u0103rii. Produsele noastre pot concura cu produse cu pre\u0163uri mai mici, compensate, cu performan\u0163\u0103 superioar\u0103, sunt u\u015for de administrat sau concureaz\u0103 \u00een alt mod cu produsele noastre. \u00cen plus, de\u015fi Amgen \u015fi partenerii s\u0103i ob\u0163in periodic brevete pentru produsele \u015fi tehnologia lor, protec\u0163ia oferit\u0103 de brevete \u015fi de cererile de brevet produselor noastre poate fi pus\u0103 la \u00eencercare, anulat\u0103 sau \u00een\u015felat\u0103 de c\u0103tre competitorii no\u015ftri sau ai partenerilor no\u015ftri \u015fi nu se pot oferi garan\u0163ii \u00a0privind abilitatea noastr\u0103 sau a partenerilor no\u015ftri de a ob\u0163ine sau men\u0163ine protec\u0163ia prin brevet pentru produsele noastre sau candidatele la statutul de produs. Nu putem garanta c\u0103 vom putea realiza produse cu succes pe pia\u0163\u0103 sau c\u0103 vom putea men\u0163ine succesul comercial al produselor noastre existente. Pre\u0163ul ac\u0163iunilor noastre poate fi afectat de oportunitatea efectiv\u0103 sau perceput\u0103 pe pia\u0163\u0103, pozi\u0163ia competitiv\u0103 \u015fi succesul sau e\u015fecul produselor noastre sau al candidatelor la statutul de produs. Mai mult, descoperirea problemelor semnificative la un produs similar cu unul dintre produsele noastre care implic\u0103 o clas\u0103 \u00eentreag\u0103 de produse ar putea avea un efect negativ puternic asupra v\u00e2nz\u0103rilor produselor afectate \u015fi asupra activit\u0103\u0163ii noastre \u015fi a rezultatelor opera\u0163iunilor. Eforturile noastre de integrare a opera\u0163iunilor companiilor pe care le-am preluat \u00a0ar putea s\u0103 nu aib\u0103 succes. Este posibil s\u0103 ne confrunt\u0103m cu dificult\u0103\u0163i, \u00eent\u00e2rzieri sau costuri nea\u015fteptate \u015fi s\u0103 nu ob\u0163inem beneficiile \u015fi reducerile de costuri anticipate \u00een planul nostru de reorganizare continu\u0103. Performan\u0163a noastr\u0103 \u00een afaceri ar putea afecta sau limita capacitatea Consiliului nostru de administra\u0163ie de a declara un dividend sau capacitatea lor de a pl\u0103ti un dividend sau de a r\u0103scump\u0103ra capitalul nostru ini\u0163ial.<\/p>\n<p>Informa\u0163iile \u015ftiin\u0163ifice discutate \u00een acest comunicat de pres\u0103 cu privire la candidatele noastre la statutul de produs sunt limitate la teritoriul Uniunii Europene. Astfel de candidate la statutul de produs nu sunt aprobate de Administra\u0163ia pentru Alimente \u015fi Medicamente din SUA sau de Comisia European\u0103 \u015fi nu se pot trage \u015fi nu trebuie trase concluzii privind siguran\u0163a sau eficacitatea candidatelor la statutul de produs.<\/p>\n<p>&nbsp;<\/p>\n<p>CONTACT:<\/p>\n<p>Amgen, Rom\u00e2nia<\/p>\n<p><strong>G\u00e1bor Sztaniszl\u00e1v<\/strong><strong>, <\/strong>Director General Amgen Rom\u00e2nia<\/p>\n<p>+40 725 355 353<\/p>\n<p><strong>Cristina Neac\u0219u, <\/strong>Director Medical Amgen Rom\u00e2nia<\/p>\n<p>+40 722 671 703<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Referin\u0163e<\/strong><strong>:<\/strong><\/p>\n<p>1. National Cancer Institute, National Institute of Health, U.S. Dept. of Health and Human Services. <em>What You Need to Know<\/em><\/p>\n<p><em>A<\/em><em>bou<\/em><em>t Melanoma and Other Skin Cancers<\/em>. June 2010<a href=\"http:\/\/www.cancer.gov\/cancertopics\/wyntk\/skin\">.http:\/\/www.cancer.gov\/cancertopics\/wyntk\/skin<\/a>. Accessed October 8, 2015.<\/p>\n<p>2. Melanoma Skin Cancer Overview. American Cancer Society.<a href=\"http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/003063-pdf.pdf\"> http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/003063-pdpdf<\/a>. Accessed October 8, 2015.<\/p>\n<p>3. Skin cancer incidence statistics. Cancer Research UK. <a href=\"http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-\">http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-<\/a> statistics\/statistics-by-cancer-type\/skin-cancer\/incidence#heading-Six. Accessed October 8, 2015.<\/p>\n<p>4. GLOBOCAN 2012. <a href=\"http:\/\/globocan.iarc.fr\/old\/summary_table_site-html.asp?selection=16120&amp;amp;title=Melanoma%2Bof%2Bskin&amp;amp;sex=0&amp;amp;type=1&amp;amp;window=1&amp;amp;europe=4&amp;amp;sort=0&amp;amp;submit=%C2%A0Execute\">http:\/\/globocan.iarc.fr\/old\/summary_table_site-<\/a><\/p>\n<p><a href=\"http:\/\/globocan.iarc.fr\/old\/summary_table_site-html.asp?selection=16120&amp;amp;title=Melanoma%2Bof%2Bskin&amp;amp;sex=0&amp;amp;type=1&amp;amp;window=1&amp;amp;europe=4&amp;amp;sort=0&amp;amp;submit=%C2%A0Execute\">html.asp?selection=16120&amp;title=Melanoma+of+skin&amp;sex=0&amp;type=1&amp;window=1&amp;europe=4&amp;sort=0&amp;submit=%C2%A0Execute.<\/a> Accessed October 12, 2015.<\/p>\n<p>5. GLOBOCAN 2012. <a href=\"http:\/\/globocan.iarc.fr\/old\/summary_table_site-html.asp?selection=16120&amp;amp;title=Melanoma%2Bof%2Bskin&amp;amp;sex=0&amp;amp;type=0&amp;amp;window=1&amp;amp;europe=4&amp;amp;sort=0&amp;amp;submit=%C2%A0Execute\">http:\/\/globocan.iarc.fr\/old\/summary_table_site- <\/a><a href=\"http:\/\/globocan.iarc.fr\/old\/summary_table_site-html.asp?selection=16120&amp;amp;title=Melanoma%2Bof%2Bskin&amp;amp;sex=0&amp;amp;type=0&amp;amp;window=1&amp;amp;europe=4&amp;amp;sort=0&amp;amp;submit=%C2%A0Execute\">html.asp?selection=16120&amp;title=Melanoma+of+skin&amp;sex=0&amp;type=0&amp;window=1&amp;europe=4&amp;sort=0&amp;submit=%C2%A0Execute.<\/a> Accessed October 12, 2015.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IMLYGIC este prima imunoterapie oncolitic\u0103 care demonstreaz\u0103 beneficii terapeutice pentru pacien\u0163ii cu melanom avansat THOUSAND OAKS, Calif. (16 noiembrie 2015) \u2013 Amgen a anun\u0163at c\u0103 CHMP (Comitetul pentru Medicamente de [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4983","post","type-post","status-publish","format-standard","category-stiri-noutati"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici\" \/>\n<meta property=\"og:description\" content=\"IMLYGIC este prima imunoterapie oncolitic\u0103 care demonstreaz\u0103 beneficii terapeutice pentru pacien\u0163ii cu melanom avansat THOUSAND OAKS, Calif. (16 noiembrie 2015) \u2013 Amgen a anun\u0163at c\u0103 CHMP (Comitetul pentru Medicamente de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-16T13:49:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC)\",\"datePublished\":\"2015-11-16T13:49:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\"},\"wordCount\":2621,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg\",\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\",\"name\":\"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg\",\"datePublished\":\"2015-11-16T13:49:24+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg\",\"width\":338,\"height\":93},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/","og_locale":"ro_RO","og_type":"article","og_title":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici","og_description":"IMLYGIC este prima imunoterapie oncolitic\u0103 care demonstreaz\u0103 beneficii terapeutice pentru pacien\u0163ii cu melanom avansat THOUSAND OAKS, Calif. (16 noiembrie 2015) \u2013 Amgen a anun\u0163at c\u0103 CHMP (Comitetul pentru Medicamente de [&hellip;]","og_url":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/","og_site_name":"Jurmed - Medici","article_published_time":"2015-11-16T13:49:24+00:00","og_image":[{"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg","type":"","width":"","height":""}],"author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"13 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC)","datePublished":"2015-11-16T13:49:24+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/"},"wordCount":2621,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg","articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/","url":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/","name":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC) - Jurmed - Medici","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen-300x83.jpg","datePublished":"2015-11-16T13:49:24+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/10\/amgen.jpg","width":338,"height":93},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/amgen-primeste-avizul-pozitiv-din-partea-chmp-pentru-imlygictm-talimogene-laherparepvec\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Amgen prime\u0219te avizul pozitiv din partea CHMP pentru IMLYGICTM (TALIMOGENE LAHERPAREPVEC)"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=4983"}],"version-history":[{"count":5,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4983\/revisions"}],"predecessor-version":[{"id":4990,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4983\/revisions\/4990"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=4983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=4983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=4983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}